Check out which companies are making headlines before the bell:
Pfizer — The pharmaceutical giant agreed to buy AstraZeneca's small molecule antibiotics business in a deal that could be valued at more than $1.5 billion. Pfizer also agreed to buy Medivation for approximately $14 billion earlier this week.
Royal Bank of Canada — RBC reported better-than-expected quarterly results, with funds set aside to cover bad loans falling thanks to higher oil prices. Like other Canadian lenders, RBC had seen a rise in bad loans to oil and gas companies due to declining energy prices.
Lowe's — Bank of America/Merrill Lynch added the home improvement's stock to its "US1 list of top ideas." BofAML said "we positive on sustained big-ticket demand for home improvement and believe LOW will continue to benefit from supportive macro trends including rising home prices, housing turnover and new home formation."
Fitbit — A U.S. International Trade Commission ruled Fitbit did not steal rival Jawbone's trade secrets. Jawbone accused Fitbit of infringing six patents and luring away employees to with confidential data about Jawbone's business.
Intuit — The financial software firm reported fiscal fourth-quarter adjusted earnings of 8 cents per share on revenue of $754 million, both above estimates. However, the company's revenue guidance came in below analysts' expectations, in a range between $740 million and $760 million.
Tesla Motors — Tesla announced new versions of its Model S and Model X that include longer battery range and faster acceleration.
La-Z-Boy — La-Z-Boy reported a 1.9 percent drop in same-store sales for its fiscal first quarter. The firm also posted adjusted earnings of 28 cents a share on revenue of $341 million, missing expectations.
Nimble Storage — The data storage company posted a wider-than-expected adjusted loss and revenues below estimates. CEO Suresh Vasudevan said in a statement "we saw strong momentum in customer and channel partner adoption of our All Flash arrays."
Clovis Oncology — The drugmaker's stock soared 7.5 percent in the premarket after the U.S. Food and Drug Administration accepted the company's application for accelerated approval of rucaparib, an anti-cancer agent.
— Reuters contributed to this report.